Current Cancer Drug Targets

Editor-in-Chief:

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
USA

Back

Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics

Volume:10   Issue:4
Pp: 354-367
M.R. Pitman and S.M. Pitson
DOI: 10.2174/156800910791208599

Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent

Volume:10   Issue:4
Pp: 368-383
L. Tentori, A. Muzi, A.S. Dorio, M. Scarsella, C. Leonetti, G.M. Shah, W. Xu, E. Camaioni, B. Gold, R. Pellicciari, F. Dantzer, J. Zhang and G. Graziani
DOI: 10.2174/156800910791208571

Targeting CREB for Cancer Therapy: Friend or Foe

Volume:10   Issue:4
Pp: 384-391
X. Xiao, B.X. Li, B. Mitton, A. Ikeda and K.M. Sakamoto
DOI: 10.2174/156800910791208535

Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer

Volume:10   Issue:4
Pp: 392-401
B. Wegiel, S. Evans, R. Hellsten, L.E. Otterbein, A. Bjartell and J.L. Persson
DOI: 10.2174/156800910791208562

Recent Advances in Understanding Hormonal Therapy Resistant Prostate Cancer

Volume:10   Issue:4
Pp: 402-410
K.V. Donkena, H. Yuan and C.Y. Young
DOI: 10.2174/156800910791208544

Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy

Volume:10   Issue:4
Pp: 411-421
S. Cruet-Hennequart, A.M. Prendergast, F.P. Barry and M.P. Carty
DOI: 10.2174/156800910791208553

Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells

Volume:10   Issue:4
Pp: 422-431
S. Carloni, F. Fabbri, G. Brigliadori, P. Ulivi, R. Silvestrini, D. Amadori and W. Zoli
DOI: 10.2174/156800910791208580